Narrative review / 2014
Oral yeast-derived beta-glucans reduced upper respiratory infections in susceptible individuals and influenced various immune markers across studies.
This review evaluates the effects of orally administered yeast-derived beta-glucans (Y-BG). In human trials, Y-BG significantly reduced the incidence of upper respiratory tract infections in susceptible individuals, but not in healthy subjects, while altering markers such as salivary IgA, IL-10 in obese subjects, and monocytes in cancer patients. Studies evaluated doses ranging from 7.5 to 1500 mg/day across preparations varying in structure, molecular weight, and solubility. Animal studies also showed protective and antineoplastic enhancement effects.
- Study type
- Narrative review
- Who was studied
- Human trials (susceptible, healthy, obese, allergic, cancer subjects) and animal models
- What was measured
- Upper respiratory tract infections, immune markers, antineoplastic and protective effects
THE PAPER
Effects of orally administered yeast-derived beta-glucans: a review.
Samuelsen AB, Schrezenmeir J, Knutsen SH. Mol Nutr Food Res, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.